Drug profile · INN
glucagon
BAQSIMI
glucagon (BAQSIMI) is a glucagon receptor agonist. Associated with Amphastar France Pharmaceuticals. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — glucagon
- US status
- approved
- Class
- Systemic hormonal preparations (H04)
- Route
- INTRAVENOUS
- Patents
- 3
- Programs
- 7
- Data quality
- 0.89
Quick answer
glucagon (BAQSIMI) is a glucagon receptor agonist. Associated with Amphastar France Pharmaceuticals. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucagon receptor agonist
Primary target: Glucagon receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is glucagon?
glucagon (BAQSIMI) is a glucagon receptor agonist. Associated with Amphastar France Pharmaceuticals. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for glucagon?
BAQSIMI is a marketed brand name for glucagon. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of glucagon?
glucagon has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.